[English]  [Pусский]  [中文]  
 
ctt-journal > Minaeva et al. (Abstract)

Minaeva et al. (Abstract)

Cellular Therapy and Transplantation (CTT), Vol. 3, No. 12
doi: 10.3205/ctt-2011-No12-abstract58

© The Authors. This abstract is provided under the following license: Creative Commons Attribution 3.0 Unported

Abstract accepted for "5th Raisa Gorbacheva Memorial Meeting Hematopoietic Stem Cell Transplantation in Children and Adults", Saint Petersburg, Russia, September 18–20, 2011

Preliminary Program

Contribute a comment

 

Effectiveness of bortezomib in autologous HSCT in patients with multiple myeloma

Natalia V. Minaeva, Natalia A. Zorina, Tamara P. Zagoskina, Eugenii P. Svedentsov, Konstantin A. Martynov, Olga V. Malykh

FGI "Kirov Institute of Hematology and Blood Transfusion of FMBA of Russia", Kirov, Russia

Correspondence: Natalia V. Minaeva, FGI "Kirov Institute of Hematology and Blood Transfusion of FMBA of Russia", 72, Krasnoarmeiskaya str., 610027, Kirov, Russia, E-mail: mnvgem@spam is badgmail.com

Abstract

High-dose chemotherapy with autologous hematopoietic stem-cell transplantation (HSCT) in multiple myeloma (MM) is a modern and highly effective method of therapy. However, the frequency of relapse remains high. A promising option in these settings is the use of targeted therapies such as bortezomib during induction and consolidation of remission.

The aim of the study was to evaluate the effectiveness of therapy with bortezomib in autoHSCT in patients with multiple myeloma.

Materials and methods: The study included 26 patients: 14 males (54%), and 12 females (46%), with a median age of 49 years (range 34–62). Induction chemotherapy in 13 patients (50%) included 3 courses of the program VAD + EDAP; the other 13 (50%) patients were treated by PAD + EDAP therapy. The following stage of pre-transplantation preparation in both groups was HSC mobilization with high-dose Cph, and conditioning Mel 200 mg/m2 and Mel 200 mg/m2 + bortezomib, respectively.

Results: Complete remission was achieved in 11 patients (85%) with conditioning Mel 200 mg/m2 + bortezomib, and only in 7 (54%) after the regimen of Mel 200 mg/m2. Median follow up period was 24 months (range 7–55). Early mortality due to invasive aspergillosis was similar in both regimens of conditioning.

Conclusion: The results showed that the inclusion of bortezomib in induction therapy and conditioning has improved the efficiency of autoHSCT with comparable toxicity in patients with MM.

Keywords: multiple myeloma, autoHSCT, bortezomib